Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

We recently published a list of 10 Firms Lead Rally on Impressive Q1 Earnings, Optimistic Outlooks. In this article, we are ...

Hims & Hers Health, Inc. HIMS is scheduled to report first-quarter 2025 results on May 5, after the closing bell. In the last ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

A decision is expected in the fourth quarter of 2025.

The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...